Completed PHASE3 INTERVENTIONAL 3-arm NCT03023111

Miltefosine and GM-CSF in Cutaneous Leishmaniasis

Miltefosine and GM-CSF in Cutaneous Leishmaniasis: a Randomized and Controlled Trial

Sponsor: Hospital Universitário Professor Edgard Santos

Interventions Miltefosine plus GM-CSF Miltefosine plus placebo Sbv

Updated 7 times since 2017 Last updated: Apr 3, 2020 Started: Jun 30, 2017 Primary completion: Aug 9, 2019 Completion: Feb 14, 2020

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03023111, this PHASE3 trial focuses on Cutaneous Leishmaniasis and remains completed. Sponsored by Hospital Universitário Professor Edgard Santos, it has been updated 7 times since 2017, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
May 2020 — Jan 2021 [monthly]

Completed PHASE3

Status: Unknown Status → Completed
Oct 2019 — May 2020 [monthly]

Unknown Status PHASE3

Status: Not Yet Recruiting → Unknown Status

▶ Show 2 earlier versions

Jun 2018 — Oct 2019 [monthly]

Not Yet Recruiting PHASE3
Feb 2017 — Jun 2018 [monthly]

Not Yet Recruiting PHASE3

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Hospital Universitário Professor Edgard Santos
Oswaldo Cruz Foundation

Data source: Hospital Universitário Professor Edgard Santos

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Manaus, Brazil
• Presidente Tancredo Neves, Brazil